- Capital Cube•yesterday
Categories: Yahoo Finance Get free summary analysis IntelGenx Technologies Corp. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of IntelGenx Technologies Corp. – Valeant Pharmaceuticals International Inc and Intellipharmaceutics International Inc. (VRX-CA and I-CA) that have also reported for this period. Highlights Summary numbers: Revenues of CAD ... Read more (Read more...)
- Marketwired•3 days agoIntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain
IntelGenx Corp., , today announced the successful completion of a pilot clinical study for Montelukast VersaFilm that demonstrated a significantly improved pharmacokinetic profile against the reference ...
- Associated Press•14 days ago
On a per-share basis, the Ville Saint Laurent, Quebec-based company said it had a loss of 1 cent. The drug delivery technology company posted revenue of $672,000 in the period. In the final minutes of ...
IntelGenx Technologies Corp. (IGX.V)
TSXV - TSXV Delayed Price. Currency in CAD
|Day's Range||1.01 - 1.12|
|52wk Range||0.54 - 1.15|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||∞|
|Avg Vol (3m)||18,348|
|Dividend & Yield||N/A (N/A)|